Warminsko-Mazurskie Centrum Chorob Pluc W Olsztynie
- Address
- lock Available on a paid plan
Warminsko-Mazurskie Centrum Chorob Pluc W Olsztynie - Pulmonary Oncology Research Center
The Warminsko-Mazurskie Centrum Chorob Pluc W Olsztynie is a specialized pulmonary disease center with extensive expertise in lung cancer clinical research. The center has established itself as a prominent investigational site conducting advanced phase 2 and phase 3 trials across the full spectrum of lung malignancies, from early-stage resectable disease to advanced metastatic presentations.
- Non-Small Cell Lung Cancer (NSCLC) - spanning all stages including targeted therapies for EGFR mutations, ALK rearrangements, KRAS G12C mutations, HER2 alterations, and ROS1/RET fusions
- Small Cell Lung Cancer (SCLC) - both extensive-stage and limited-stage disease with novel immunotherapy combinations
- Precision Medicine Approaches - biomarker-driven trials utilizing PD-L1 expression, tumor mutational burden, and circulating tumor DNA (ctDNA) detection
- Immunotherapy Combinations - extensive experience with checkpoint inhibitors including pembrolizumab, durvalumab, atezolizumab, and novel agents combined with chemotherapy or targeted therapies
The center demonstrates particular strength in evaluating neoadjuvant and adjuvant treatment strategies for resectable NSCLC, as well as maintenance therapy approaches following first-line treatment. Their research portfolio includes groundbreaking studies with antibody-drug conjugates such as trastuzumab deruxtecan and datopotamab deruxtecan, combined with immunotherapy agents. The center also participates in innovative platform trials and biosimilar development studies, contributing to the advancement of personalized medicine in thoracic oncology with a focus on improving outcomes across diverse molecular subtypes and disease stages.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 6 therapeutic areas and 15 of 93 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 91 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 17 by active trials.
- 1Merck Sharp & Dohme LLC9active
lock +16 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB16trials
lock +8 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Warminsko-Mazurskie Centrum Chorob Pluc W Olsztynie
lock Showing 1 of 74 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Comparative Study of ABP 234 and Pembrolizumab in Patients with Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer | Amgen Inc. | Phase I | Recruiting | Oct 2024 | — |
IMP list
lock Showing 1 of 93 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 30 | Unknown | 2018-08-24 | 2026-06-16 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.